DBV Technologies

In case you missed it, we presented long-term data from the Phase 3 PEOPLE Study at the American Academy of Allergy, Asthma and Immunology - AAAAII / World Allergy Organization joint congress, including the efficacy and safety of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4-11 years. Access the abstract here to learn more: https://bit.ly/4ctzuZC

We are pleased to announce a financing of up to $306.9 Million to advance Viaskin® Peanut Patch for #PeanutAllergy through a Biologic License Application (BLA) submission and U.S. commercial launch, if approved. Join our investor conference call on Monday, 3/31 at 5pm ET and read the release to learn more: https://bit.ly/3DXLkOT

This week, we’re attending the American College of Allergy, Asthma and Immunology (ACAAI)’s Inaugural Cherry Blossom Allergy Conference. We look forward to engaging with peers on the latest advancements in #allergy research, including our ongoing work at DBV. Stop by our booth to learn more! See conference details here: https://bit.ly/4liGhJU #CBAC

Clinical evidence from the Phase 3 REALISE Study evaluating the long-term safety profile of our investigational treatment option in children with #PeanutAllergy was published in The Journal of Allergy and Clinical Immunology: In Practice (JACI). Read the peer-reviewed article to learn more: https://bit.ly/4lcwDIK

We are delighted to announce that the U.S. Food and Drug Administration (FDA) has agreed that the safety exposure data from the VITESSE Phase 3 study and the Open-Label Extension will be sufficient to support a Biologic License Application (BLA) of our investigational treatment option in 4–7-year-olds with #PeanutAllergy, accelerating the timeline for a BLA filing to 1H2026. Learn more here and see our 2024 financial results: https://bit.ly/4kUqr82

We’re pleased to share that The Journal of Allergy and Clinical Immunology: In Practice (JACI) published an assessment from the first year of our Phase 3 EPITOPE extension study evaluating epicutaneous immunotherapy in peanut-allergic toddlers. Read the peer-reviewed article to learn more: https://bit.ly/4kzCozX

#DYK? March is #NationalNutritionMonth! For those living with #FoodAllergies, nutrition isn’t just about health – it’s about safety and inclusion. At DBV, we’re committed to advancing an investigational treatment option that addresses the needs of young children and families affected by food allergies. Learn more about the importance of nutrition and join us in raising awareness: https://bit.ly/3QKO8kq

Today, we’re heading off to the Allergy, Asthma, and Immunology Society of South Carolina Annual Meeting! Visit our booth to explore how we’re advancing an investigational treatment option for children and toddlers with #PeanutAllergy. For conference details: https://bit.ly/3R8uv6S #AAISSC

On Day 4 of the American Academy of Allergy, Asthma and Immunology - AAAAI and World Allergy Organization joint congress, don’t miss our oral abstract presentation by Dr. David Fleischer on the end-of-study efficacy and safety results from the Phase 3 PEOPLE Study in peanut-allergic children aged 4-11 years. See here for presentation highlights and details: https://bit.ly/4ieWmh4 #AAAAI25 #WAO #WAC2025

On Day 2 of the American Academy of Allergy, Asthma and Immunology - AAAAI and World Allergy Organization joint congress, we are hosting a non-CME #ProductTheater on the key attributes of epicutaneous immunotherapy. Join today for expert insights from Professors Hugh Sampson, MD, Helen Brough, MBBS, PhD, and moderator Douglas Mack, MSc, MD. For details: https://bit.ly/4ieWmh4 #AAAAI25 #WAO #WAC2025